ScholarIQanswers from OpenAlex & ORCID
Hisao Ogawa
ResearcherPublications, citations & collaboration network
Hisao Ogawa is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hisao Ogawa have?
ScholarIQindexed works
Hisao Ogawa has 1,721 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hisao Ogawa have?
ScholarIQcitation count
Hisao Ogawa has 61,658 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hisao Ogawa?
ScholarIQh-index
Hisao Ogawa has an h-index of 108 in OpenAlex.
What is the i10-index of Hisao Ogawa?
ScholarIQi10-index
Hisao Ogawa has an i10-index of 653 in OpenAlex.
What is the ORCID of Hisao Ogawa?
ScholarIQorcid
The ORCID for Hisao Ogawa is on the source record.
What is the OpenAlex record for Hisao Ogawa?
ScholarIQopenalex
The OpenAlex for Hisao Ogawa is on the source record.
What are the most-cited papers on Hisao Ogawa?
ScholarIQmost cited works
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Brendan M. Everett, Tom Thurén, Jean MacFadyen, William H. Chang, Christie M. Ballantyne, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Wolfgang Köenig, Stefan D. Anker, John J.P. Kastelein, Jan H. Cornel, Prem Pais, Daniel Pella, Jacques Genest, Renata Cífková, Alberto Lorenzatti, Tamás Forster, Zhanna Kobalava, L Vida-Simiti, Marcus Flather, Hiroaki Shimokawa, Hisao Ogawa, Mikael Dellborg, Paulo R.F. Rossi, Roland P.T. Troquay, Peter Libby, Robert J. Glynn
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
Hirofumi Yasue, Michihiro Yoshimura, Hayakazu Sumida, K Kikuta, Kiyotaka Kugiyama, Michihisa Jougasaki, Hisao Ogawa, Kazuhiro Okumura, Masashi Mukoyama, Kōichi Nakao
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker, Jean MacFadyen, Tom Thurén, Brendan M Everett, Peter Libby, Robert J. Glynn, Paul M. Ridker, Alberto Lorenzatti, Henry Krum, George Varigos, Peter Siostrzonek, Peter Sinnaeve, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Nina Gotcheva, Jacques Genest, Yong Huo, Miguel Urina‐Triana, Davor Miličić, Renata Cífková, Riina Vettus, Wolfgang Köenig, S.D. Anker, Athanasios Manolis, Fernando Wyss, Tamás Forster, Axel F. Sigurðsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birutė Petrauskienė, Leon Salvador, John J.P. Kastelein, Jan H. Cornel, Tor Ole Klemsdal, Félix Medina, Andrzej Budaj, L Vida-Simiti, Zhanna Kobalava, Petar Otašević, Daniel Pella, Mitja Lainščak, Ki‐Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Y. Donath, Juey‐Jen Hwang, Hakan Kültürsay, Marcus Flather, Christie M. Ballantyne, Seth Bilazarian, William H. Chang, Cara East, Brendan Everett, Les B. Forgosh, Robert J. Glynn, Barry Harris, Peter Libby, M Ligueros, Tom Thurén, Erin A. Bohula, Bindu Charmarthi, Susan Cheng, Sherry Chou, Jacqueline Suk Danik, Graham T. McMahon, Bradley A. Maron, MingMing Ning, Benjamin A. Olenchock, Reena L. Pande, Todd S. Perlstein, Aruna D. Pradhan, Natalia S. Rost, Aneesh B. Singhal, Viviany R. Taqueti, Nancy Wei, Howard A. Burris, Angela Cioffi, Anne Marie Dalseg, Nilanjan Ghosh, Julie R. Gralow, Tina Mayer, Hope S. Rugo, Vance G. Fowler, Ajit P. Limaye, Sara E. Cosgrove, Donald P. Levine, Renato D. Lópes, John Scott, Tom Thurén, M Ligueros, Robert Hilkert, Georgia Tamesby, Carolyn Mickel, Brian Manning, Julian Woelcke, Monique Tan, S Manfreda
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
John H. Alexander, Renato D. Lópes, Stefan James, Rakhi Kilaru, Yaohua He, Puneet Mohan, Deepak L. Bhatt, Shaun G. Goodman, Freek W.A. Verheugt, Marcus Flather, Kurt Huber, Danny Liaw, Steen Husted, José López‐Sendón, Raffaele De Caterina, Petr Janský, Harald Darius, Dragoş Vinereanu, Jan H. Cornel, Frank Cools, Dan Atar, José L. Leiva-Pons, Mátyás Keltai, Hisao Ogawa, Prem Pais, Alexander Parkhomenko, Witold Rużyłło, Rafael Díaz, Harvey D. White, Mikhail Ruda, Margarida Geraldes, Jack Lawrence, Robert A. Harrington, Lars Wallentin
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker, Jean MacFadyen, Brendan M Everett, Peter Libby, Tom Thurén, Robert J. Glynn, Paul M. Ridker, Jean MacFadyen, Brendan M Everett, Peter Libby, Tom Thurén, Robert J. Glynn, John J.P. Kastelein, Wolfgang Köenig, Jacques Genest, Alberto Lorenzatti, George Varigos, Peter Siostrzonek, Peter Sinnaeve, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Nina Gotcheva, Yong Huo, Miguel Urina‐Triana, Davor Miličić, Renata Cífková, Riina Vettus, S.D. Anker, Athanasios Manolis, Fernando Wyss, Tamás Forster, Axel F. Sigurðsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birutė Petrauskienė, Leon Salvador, Jan H. Cornel, Tor Ole Klemsdal, Félix Medina, Andrzej Budaj, L Vida-Simiti, Zhanna Kobalava, Petar Otašević, Daniel Pella, Mitja Lainščak, Ki‐Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Y. Donath, Juey‐Jen Hwang, Hakan Kültürsay, Marcus Flather, Christie M. Ballantyne, Seth Bilazarian, William H. Chang, Cara East, Les B. Forgosh, Barry Harris, M Ligueros